Renaissance Technologies LLC Lowers Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Renaissance Technologies LLC cut its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 32.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,938,145 shares of the company’s stock after selling 945,600 shares during the quarter. Renaissance Technologies LLC owned about 2.72% of Zentalis Pharmaceuticals worth $4,535,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. 5AM Venture Management LLC lifted its position in Zentalis Pharmaceuticals by 705.7% during the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after buying an additional 3,457,913 shares during the period. Millennium Management LLC grew its position in shares of Zentalis Pharmaceuticals by 220.6% in the 1st quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after buying an additional 2,111,951 shares during the period. Vanguard Group Inc. grew its position in shares of Zentalis Pharmaceuticals by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock worth $4,386,000 after buying an additional 19,768 shares during the period. Bank of America Corp DE increased its stake in shares of Zentalis Pharmaceuticals by 117.1% in the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock worth $2,339,000 after acquiring an additional 835,466 shares in the last quarter. Finally, Opaleye Management Inc. increased its stake in shares of Zentalis Pharmaceuticals by 342.6% in the 4th quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after acquiring an additional 1,084,356 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ZNTL shares. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Guggenheim upped their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Mizuho began coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $6.75.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $5.00 on Friday. The company has a market capitalization of $355.95 million, a price-to-earnings ratio of -2.89 and a beta of 1.92. Zentalis Pharmaceuticals, Inc. has a one year low of $1.21 and a one year high of $6.95. The company’s 50-day moving average is $4.31 and its 200 day moving average is $3.59.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). As a group, research analysts predict that Zentalis Pharmaceuticals, Inc. will post -1.83 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.